Tempus announces collaboration with united therapeutics to study use of ai to detect patients at risk for pulmonary hypertension

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a leader in artificial intelligence and precision medicine, today announced a new collaboration with united therapeutics (ut), a leading biotechnology company focused on providing a brighter future for patients through the development of novel pharmaceuticals and technologies. as part of this collaboration, tempus will develop and investigate ai-based medical device software to detect patients at risk of having undiagnosed pulmonary hyper.
TEM Ratings Summary
TEM Quant Ranking